Audra Cook
Family Medicine · Ada, OKNPI 1326074113
Payments from drug & device makers
Across 88 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$343
- Astellas Pharma US Inc$193
- Pfizer$142
- Novo Nordisk$130
- Amgen$92
- GSK$70
- plus $494 from 18 others
What the payments were for
- Food & beverage$1,25586%
- Education$20814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $343 |
| Astellas Pharma US Inc | 3 | $193 |
| Pfizer | 10 | $142 |
| Novo Nordisk | 8 | $130 |
| Amgen | 6 | $92 |
| GSK | 5 | $70 |
| Boehringer Ingelheim | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Lilly USA, LLC | 3 | $41 |
| Eisai Inc. | 3 | $39 |
| AbbVie(2 entities) | 3 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Vapotherm Inc | 1 | $15 |
| Merck | 1 | $13 |
| Millicent US Inc | 1 | $13 |
| Insulet Corporation | 1 | $12 |
| Dermira, Inc. | 1 | $11 |
How this compares
$1,463 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 25 | $19,012 |
| JardianceEmpagliflozin | 16 | $16,832 |
| OzempicSemaglutide | 14 | $12,852 |
| Pregabalin | 17 | $2,009 |
| Citalopram HbrCitalopram Hydrobromide | 21 | $1,124 |
| Memantine Hcl | 17 | $918 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $763 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $710 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $576 |
| Atorvastatin Calcium | 53 | $566 |
| Levothyroxine Sodium | 50 | $552 |
| Gabapentin | 51 | $523 |
| Duloxetine Hcl | 15 | $472 |
| Esomeprazole Magnesium | 15 | $327 |
| Celecoxib | 13 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $19,01225 claims |
| Boehringer IngelheimJardiance | $51 | $16,83216 claims |
| Novo NordiskOzempic | $130 | $12,85214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Ada
- Curtis HarrisAda$125K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.